Also known as: 1-aminoadamantane Amantadine Amantadine hydrochloride
Amantadine has been shown to be a low affinity antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Overactivity of glutamatergic neurotransmission has been implicated in the generation of parkinsonian symptoms. In addition, amantadine specifically inhibits the replication of influenza A viruses at low concentrations.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Amantadine is the active ingredient of these drugs:
Hong Kong
Tunisia
Poland
Hong Kong
United States
France
Brazil
United States
Austria Estonia Hong Kong Lithuania
South Africa
Australia Hong Kong Netherlands New Zealand Singapore
Poland
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):